MedTrace Logo

Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

NCT06688838 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2026-01-27

No results posted yet for this study

Summary

To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.

Conditions

  • Blau Syndrome

Interventions

DRUG

Tofacitinib

If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Affiliated Hospital of Yunnan University

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Wuhan Women and Children's Medical Center

    collaborator OTHER

  • Johns Hopkins Community Physicians

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06688838 on ClinicalTrials.gov